Yale Jen

“And I'm just about to follow up from the previous one, a similar line, which is that for 2019, Although this current study, the phase one study is all commerce, but strategically when you're going forward, maybe into the phase two or other late stage studies, would you be focusing more on certain patients or you will…”

“My first one is that in terms of FG, we understand the first quarter figure was due to the shipment, timing of shipments. So should we anticipate for the second and third quarter you will get back to the level similar to last year and it sort of make up for the differences.”

“Your oral compound now is pushed out probably roughly a year compared to 7737. My question to you is that do you see any challenges to have that become R&D ready? next year.”

“In terms of the vanquish expansion study itself, would that also include both vanquish 1 and vanquish 2 in terms of the type 2 diabetes patients, as well as if you would incorporate some maintenance regimen into those in that study?”

“The first one is based on the guidance for the 2020 state. We believe that diagnostic on the business seems to be having a continuous growth quarter over quarter in that pattern.”